Three Novel Calreticulin Mutations in Two Turkish Patients

Three Novel Calreticulin Mutations in Two Turkish Patients

Bibliographic Details
Main Authors:	Veysel Sabri Hançer, Hüseyin Tokgöz, Serkan Güvenç, Ümran Çalışkan, Murat Büyükdoğan
Format:	Article
Language:	English
Published:	Galenos Publishing House 2017-11-01
Series:	Turkish Journal of Hematology
Subjects:	essential thrombocythemia primary myelofibrosis calreticulin
Online Access:	https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-16878

Similar Items

Calreticulin in Essential Thrombocythemia: StressINg OUT the Megakaryocyte Nucleus
by: Francisco Jose Iborra, et al.
Published: (2017-05-01)

Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study
by: Chao Sun, et al.
Published: (2016-01-01)

Calreticulin mutation survey by high resolution melting method associated with unique presentations in essential thrombocythemic patients
by: Yi-Chang Liu, et al.
Published: (2020-04-01)

FREQUENCY OF CALR GENE MUTATION IN MYELOPROLIFERATIVE NEOPLASMS
by: Sana Latif, et al.
Published: (2020-04-01)

Comparison of molecular genetic methods of detection of mutations in the CALR gene in myeloproliferative disorders
by: L. A. Kesaeva, et al.
Published: (2019-07-01)

Calreticulin—Enigmatic Discovery
by: Gillian C. Okura, et al.
Published: (2024-07-01)

Essential thrombocythemia with (type2) calreticulin presented as stuttering priapism case report and review of literature
by: Elrazi Awadelkarim Ali, et al.
Published: (2021-01-01)

Development and validation of a model for the early prediction of progression from essential thrombocythemia to post-essential thrombocythemia myelofibrosis: a multicentre retrospective studyResearch in context
by: Danhong Xiang, et al.
Published: (2024-01-01)

Recent insights regarding the molecular basis of myeloproliferative neoplasms
by: Mi-Ae Jang, et al.
Published: (2020-01-01)

Invasive ductal breast carcinoma preceded by CALR‐positive essential thrombocythemia
by: Elrazi A. Ali, et al.
Published: (2021-03-01)

MPL W515L/K Mutations in Chronic Myeloproliferative Neoplasms
by: Timur Selçuk Akpınar, et al.
Published: (2013-03-01)

C-Mannosyl tryptophan is a novel biomarker for thrombocytosis of myeloproliferative neoplasms
by: Shotaro Tabata, et al.
Published: (2024-08-01)

The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
by: Sung-Yong Kim, et al.
Published: (2021-01-01)

Evaluation of the Relationship between Janus Kinase 2 Mutational Burden and Clinical Findings in Adult Myeloproliferative Neoplasm Patients
by: Cigdem Yuce Kahraman, et al.
Published: (2022-01-01)

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis
by: İpek Yonal, et al.
Published: (2016-05-01)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
by: Hisashi Ishida, et al.
Published: (2020-07-01)

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018
by: Mónica Mejía-Ochoa, et al.
Published: (2019-06-01)

Pediatric Philadelphia-Negative Myeloproliferative Neoplasms in the Era of WHO Classification: A Systematic Review
by: Abdulrahman F. Al-Mashdali, et al.
Published: (2023-01-01)

The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
by: Graeme Greenfield, et al.
Published: (2018-12-01)

A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms
by: Tarinee Rungjirajittranon, et al.
Published: (2019-02-01)

Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms
by: Moysés Antonio Porto-Soares, et al.
Published: (2020-07-01)

New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options
by: Domenico Penna
Published: (2021-10-01)

Molecular study of CALR gene mutations in children with leukemia hospitalized in Kerman hospitals
by: Farzaneh Parnak, et al.
Published: (2020-03-01)

Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post‐essential thrombocythemia myelofibrosis: A case report
by: Mahija Cheekati, et al.
Published: (2024-04-01)

Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis
by: Marko Lucijanic, et al.
Published: (2024-04-01)

Primary Arterial Hypertension and Drug-Induced Hypertension in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review
by: Mihnea-Alexandru Găman, et al.
Published: (2023-01-01)

Smoking is associated with increased risk of myeloproliferative neoplasms: A general population‐based cohort study
by: Kasper M. Pedersen, et al.
Published: (2018-11-01)

Thrombosis in myeloproliferative neoplasms: A clinical and pathophysiological perspective
by: Sarah Kelliher, et al.
Published: (2021-12-01)

Unexpected high platelet counts in a potential platelet donor: A clue to essential thrombocythemia
by: Anisha Navkudkar, et al.
Published: (2020-01-01)

Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease
by: Magda Zanelli, et al.
Published: (2024-03-01)

Incidence of blast phase in myelofibrosis according to anemia severity
by: Barbara Mora, et al.
Published: (2023-08-01)

Evaluation of thrombin generation in classical Philadelphianegative myeloproliferative neoplasms / Evaluarea generării trombinei în neoplasmele mieloproliferative Philadelphia- negative
by: Olteanu Ariela Ligia, et al.
Published: (2016-09-01)

A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients
by: Uzma Zaidi, et al.
Published: (2020-03-01)

Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review
by: Mihnea-Alexandru Găman, et al.
Published: (2021-07-01)

Histopathology imagery dataset of Ph-negative myeloproliferative neoplasm
by: Umi Kalsom Mohamad Yusof, et al.
Published: (2023-10-01)

Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada
by: Jonathan Heppner, et al.
Published: (2019-05-01)

Calreticulin and the Heart
by: Jody Groenendyk, et al.
Published: (2022-05-01)

The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia
by: Jingyi Wang, et al.
Published: (2016-08-01)

Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan
by: Yoko Edahiro, et al.
Published: (2024-12-01)

Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR–ABL-Negative Myeloproliferative Neoplasm
by: Alessandro Allegra, et al.
Published: (2020-10-01)